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Abstract
Endemic Burkitt’s lymphoma (eBL) arises from the germinal center (GC). It is a common tumor of young children in tropical
Africa and its occurrence is closely linked geographically with the incidence of P. falciparum malaria. This association was
noted more than 50 years ago. Since then we have learned that eBL contains the oncogenic herpes virus Epstein-Barr virus
(EBV) and a defining translocation that activates the c-myc oncogene. However the link to malaria has never been explained.
Here we provide evidence for a mechanism arising in the GC to explain this association. Accumulated evidence suggests
that eBL arises in the GC when deregulated expression of AID (Activation-induced cytidine deaminase) causes a c-myc
translocation in a cell latently infected with Epstein-Barr virus (EBV). Here we show that P. falciparum targets GC B cells via
multiple pathways to increase the risk of eBL. 1. It causes deregulated expression of AID, thereby increasing the risk of a c-
myc translocation. 2. It increases the number of B cells transiting the GC. 3. It dramatically increases the frequency of these
cells that are infected with EBV and therefore protected from c-myc induced apoptosis. We propose that these activities
combine synergistically to dramatically increase the incidence of eBL in individuals infected with malaria.
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Introduction
Endemic Burkitt’s lymphoma (eBL) is an extremely common
tumor of young children in tropical Africa [1]. Genetic,
phenotypic and transcriptional analysis suggests that it originates
from germinal center (GC) cells [2,3] although it actually grows in
extrafollicular locations. It is defined by a well described
chromosomal translocation between the c-myc oncogene and
one of the immunoglobulin loci that results in constitutive
activation of the oncogene leading to uncontrolled growth of the
cell [4,5,6]. Recent studies indicate that this translocation may be
mediated as a consequence of deregulated expression of the
enzyme AID (Activation-induced cytidine deaminase) [7,8,9]. AID
is highly expressed in GC B cells and is normally responsible for
the processes of somatic hypermutation and class switch recom-
bination of immunoglobulin genes as they undergo affinity
maturation in the GC [10]. This restricted expression of AID
further supports the notion that eBL originates in the GC.
eBL is also closely associated with two infectious agents, P.
falciparum malaria and Epstein-Barr virus (EBV) [1,11,12]. The
distribution of the tumor in Africa closely matches that of hyper-
and holoendemic malaria [12] while EBV was originally
discovered in eBL tumor biopsies. Subsequently, we have
learned a great deal about the molecular mechanism behind
eBL pathogenesis and the transforming ability of EBV. EBV is a B
lymphotropic herpes virus that can drive the activation and
proliferation of newly infected B cells by expressing a series of
latent proteins and noncoding RNAs that collectively are referred
to as the growth transcription program[13,14]. In vivo, however,
EBV establishes a lifelong, quiescent, persistent infection in resting
memory B cells [15,16]. The virus makes the transition in vivo from
a newly infected activated B cell blast to a resting memory B cell
via passage through the GCs of the tonsillar lymphoid tissue
[[17,18]. In doing so it recapitulates the mechanism by which
normal B cells become memory B cells (for a detailed description
of the mechanism see [14]).
Normally deregulation of c-myc expression such as is found in
eBL would lead to apoptotic death of the cell; however, evidence
suggests that exposure to the EBV growth program prior to entry
into the GC [14,19] and viral genes expressed in the GC [20,21]
are sufficient to convey a level of resistance to this apoptosis. Thus,
the cells in the GC most likely to tolerate the c-myc translocation
are the ones already latently infected with EBV. This also places
EBV at the site of eBL origin, the GC. Interestingly GC cells
carrying EBV express only a limited subset of the latent proteins
(default transcription program) and even these become silenced as
the infected cells enter the memory compartment [16,17,22]. Here
the virus only expresses small non-coding RNAs including ,40
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miRNAs. The exception is that they also express the viral DNA
tethering protein EBNA1 when the cells occasionally divide as part
of normal memory B cell homeostasis [23]. Viral gene expression
in eBL resembles the infected dividing memory B cells, not the GC
cell: i.e. viral gene expression is limited to the viral DNA tethering
protein (EBNA1) and the non-coding RNAs. This led us to
propose that eBL is a tumor of a GC cell that has left the lymph
node to become a resting memory B cell but is unable to do so
because it continues to proliferate, driven by the deregulated c-
myc oncogene.
While understanding the function of c-myc and EBV in eBL has
progressed, the role of P. falciparum malaria has remained poorly
understood. P. falciparum malaria is immunosuppressive [24] and
there is considerable evidence that this leads to much higher viral
burdens of EBV [25,26]. However it is well documented that
increased EB viral loads associated with immunosuppression [27]
predispose to EBV positive immunoblastic lymphoma not Burkitt’s
lymphoma [28]. We hypothesize that malaria plays multiple roles
in eBL pathogenesis. First, we propose that malaria has the
capacity to induce deregulated expression of AID thereby
increasing the likelihood of the translocation event. Second, we
suggest that the higher viral burdens lead to an increased
frequency of newly infected B cell blasts in the tonsils. This results
in more EBV infected B cells transiting the GC and consequently a
higher frequency of cells in the GC able to tolerate a c-myc
translocation. Taken together malaria infection would both
increase the likelihood of c-myc translocations in the GC and
the probability that it will occur in a cell that can tolerate it,
namely an EBV infected cell. In this paper we have sought to test
this hypothesis.
Results
Malaria parasites induce AID in B cells in vitro
To provide direct support for our hypothesis we have sought in
vitro evidence that P. falciparum can stimulate AID expression.
Tonsil B cells were incubated with malaria extract prepared by
lysing red blood cells infected with P. falciparum. As controls we
used the known Toll like receptor 9 (TLR9) agonist CpG and
costimulation with IL-4 and CD40 ligand. Figure 1A shows a time
course of AID mRNA induction with various combinations of
stimulants. It is apparent that optimal induction requires a
combination of T cell help (CD40 ligand and IL-4) and the
TLR9 agonist CpG, with peak activation occurring after 5 days of
culture. In our hands, CpG alone had minimal or no effect on AID
induction although it was extremely potent in driving B cell
proliferation (not shown). These results are consistent with previous
reports [29]. Figure 1B shows the same experiment where extracts
from lysed red blood cells infected with P. falciparum were also tested.
Similarly to CpG, the parasite extract had minimal or no effect
when added alone but showed strong stimulation of AID expression
in combination with IL-4 and CD40 ligand. This suggests that the
parasite would only stimulate AID expression when T cell help is
available, i.e. in the GC. As with CpG activity peaked by day 5. At
this time, the parasite extract was three times as effective as CpG in
inducing AID mRNA. The parasite extract differed from CpG in
that when added alone it was not able to stimulate B cell
proliferation (not shown).
Optimal stimulation of AID expression by CpG requires
costimulation through the BCR. This is demonstrated in
Figure 2, where inclusion of sIg cross-linking increased stimulation
two and a half fold compared to CpG alone. Comparison to
parasite extract in the same experiment demonstrated that sIg
cross-linking plus CpG were about as effective as parasite extract
alone and that sIg cross-linking did not significantly enhance the
effect of parasite extract. Extracts from uninfected RBCs showed
no activity either alone or in combination with other stimuli
(Figure 2). We conclude that the parasite is able to generate a
signal that is as effective as the TLR9 and BCR signals combined.
To confirm that the increase in AID mRNA stimulated by the
parasite was reflected in increased AID protein expression, we
repeated the stimulation experiments and examined the resulting
cells for AID by flow cytometry. As may be seen in Figure 3A–C,
parasite extract induced comparable levels of AID protein
expression to that achieved with CpG when combined with sIg
cross-linking. It is noteworthy that in some cases the relative level
of protein expression measured by FACS did not match the levels
seen for the mRNA (see for example Unstimulated versus CD40L
+IL4). This likely reflects that the cells are newly stimulated in
culture and there is a lag between the synthesis of AID mRNA and
the production of the protein.
We conclude, therefore, that P. falciparum is a potent antigen
independent stimulator of AID expression. When combined with
T cell help signals it is at least as effective as the combination of
CpG and BCR cross-linking.
Hemozoin is an AID agonist
It has been reported that the P. falciparum metabolic product of
hemoglobin digestion, hemozoin [30], is a ligand for TLR9, but
this has only been tested with dendritic cells [31,32]. It has not
been shown for B cells. To test if hemozoin could be taken up by B
cells we have incubated hemozoin and CpG with two B cell lines,
BL2 (EBV negative BL line) and IM171 (spontaneous EBV
positive lymphoblastoid cell line). As may be seen in Figure 4A,
both were readily taken up by the B cells (Hemozoin crystals were
visualized using reflection microscopy and CpG is tagged with
Alexa-488). To test if hemozoin could thereby act to stimulate AID
expression we have compared the stimulatory activity of hemozoin
to CpG and sIg. The result is shown in Figure 4B. Hemozoin
alone had no effect, however in combination with sIg cross-linking
it was two and a half fold more effective than sIg alone,
comparable with CpG plus sIg. No appreciable increase was
observed when parasite DNA was added (3 ug/ml) either alone or
together with hemozoin. This suggests that the hemozoin
preparation alone was sufficient for the activity.
These results demonstrate that hemozoin is one component of
the P. falciparum extract that is capable of stimulating AID
expression however there must be another component that is
mimicked by sIg cross-linking to obtain the optimal stimulation
obtained with whole parasite extracts.
Author Summary
Endemic Burkitt’s lymphoma (eBL) is a common tumor of
young children in tropical Africa that is closely linked
geographically with P. falciparum malaria. This association
was noted more than 50 years ago. Since then we have
learned that eBL contains the oncogenic herpes virus
Epstein-Barr virus and a defining translocation that
activates the c-myc oncogene. However the link to malaria
has never been explained. Here we show that malaria has
multiple effects that all focus on germinal center (GC) B
cells that are known to be the origin of eBL. Together
these effects of malaria act synergistically to dramatically
increase the risk of developing eBL in individuals infected
with the parasite. Clinical interventions that lessen the
impact of malaria on GC B cells should dramatically
decrease the incidence eBL.
Role of Malaria in Burkitt’s Lymphoma
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Figure 1. P. falciparum extracts stimulate expression of AID mRNA in normal tonsil B cells. Tonsils lymphocytes were isolated and
incubated with the components indicated in the Figure for 3 (blue), 5 (red) or 7 (green) days. After the noted incubation times, B cells were isolated
and analyzed for AID mRNA expression. A. Induction of AID mRNA requires a combination of signals from IL-4, CD40 ligand and CpG. B. P. falciparum
extracts stimulate AID mRNA expression more effectively than CpG. AU – arbitrary units. The level of AID mRNA is expressed relative to that of b-actin.
doi:10.1371/journal.ppat.1004170.g001
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Higher levels of AID expression in GCs of malaria tonsils
To test the hypothesis that malaria is associated with higher
levels of AID expression in vivo, we have examined and compared
purified GC cells from tonsils obtained from malaria infected and
uninfected patients who were matched for age, sex and
socioeconomic class. The results are summarized in Figure 5A–
B. mRNA was isolated from similar numbers of GC B cells. For all
samples AID and c-myc mRNA levels were normalized to b-actin
and the level in the GC population is expressed relative to that in a
standard naı¨ve B cell population (calibrator) isolated from a single
Boston tonsil. The level of AID mRNA in the GC cells from the
control population are comparable with what has been reported
previously [33]. In comparison, the levels of AID mRNA in the
malaria tonsils were significantly higher, about 5 fold on average.
However, although all the values for the malaria tonsil were above
the range of the controls, the spread was large such that some
samples had levels 8–13 fold higher than controls. The results for
c-myc transcripts were less striking. Most of the malaria samples
showed little or no significant difference from controls with the
exception that two of the nine samples tested clearly had a
markedly elevated level of c-myc mRNA. The level of c-myc
mRNA did not correlate with the levels of AID mRNA. These
results confirm our prediction that the levels of AID expression are
higher in the tonsil GC B cells of individuals infected with malaria.
Higher levels of GC cells and EBV infected GC cells in
malaria tonsils
To test the hypothesis that malaria is associated with higher
levels of EBV infected cells in the GC, the GC cells from the same
sets of tonsils described above were also analyzed for the presence
of EBV. We recovered similar numbers of cells from both sets of
tonsils and the fraction of B cells was also similar (Figure 6A). The
fraction of GC cells in the control tonsils was ,32% (Figure 6B),
consistent with what we have seen in previous studies. However,
the frequency in the malaria tonsils was unusually high ,50%.
When we analyzed the frequency of EBV infected cells in the two
sets of tonsils, an even more dramatic difference was observed
(Figure 6C and Table 1– note the log-scale in the Figure), with the
level being ,50 fold higher on average in the malaria tonsils
compared to controls (log mean: 2,275/107 versus 51/107; median
2,580/107 versus 52/107). Taking the increased numbers of GC
cells into account, this means that the malaria tonsils have
approximately 70 fold more EBV infected cells in their GCs.
These results confirm our prediction that the levels of EBV
infected GC B cells should be higher in the tonsils of individuals
infected with malaria.
As may be seen in Figure 6D, although both EBV infection and
AID expression were elevated in all of the malaria tonsils there was
no correlation between the levels of EBV infection and the level of
AID in either malaria or control samples. We conclude that
individuals infected with malaria have an increased level of EBV
infected cells and AID mRNA expression in their tonsil GC cells,
but these levels are not correlated.
c-myc expression in the GC
We have shown above that the level of c-myc transcripts is
significantly elevated in GC cells from the tonsils of a subset of
individuals with malaria. However, there has been controversy as
to whether c-myc is actually expressed in the GC [34,35,36,37].
Therefore, to confirm that we were detecting c-myc expression in
Figure 2. P. falciparum extracts stimulate AID expression at levels equivalent to CpG combined with surface Ig cross-linking. The
assay was performed after incubation for 5 days as described in Figure 1.
doi:10.1371/journal.ppat.1004170.g002
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GC cells we performed several experiments as shown in Figure 7.
GC cells (CD10+ tonsil B cells) were positive for c-myc expression
when stained with a c-myc specific antibody and analyzed by flow
cytometry (Figure 7A). The presence of c-myc protein in our GC
cell preparations was confirmed by Western blot (Figure 7B),
where the signal was specifically blocked by the myc specific
peptide used to raise the antibody. The specificity and correct
location of the protein in the nucleus was confirmed by analysis
with the ImageStream (Figure 7C). We conclude, therefore, that
our studies support the current opinion that c-myc is expressed in
GC cells.
Discussion
It is now more than 50 years since the association between P.
falciparum malaria and eBL was first proposed [11,12]. Since that
time, confirmation of a direct link and a mechanism to explain it
has been lacking. Here we have presented studies on the effect of
malaria in the context of the GC and provided evidence for a
multifactorial effect of malaria that can account for the increase
risk of eBL. These include the activation of AID expression,
possible heightened c-myc transcription, increasing the numbers of
B cells transiting the GC and increasing the fraction of these cells
that are EBV infected. The common component linking these
effects is the GC. The GC is the structure where immunoglobulin
genes undergo somatic hypermutation and class switch recombi-
nation [38,39], mediated by AID [10], as the cells undergo affinity
maturation. It is this enzyme that is responsible for causing the c-
myc translocation characteristic of eBL [7,8,9]. However, the GC
is also the site where newly infected EBV blasts undergo the
transition to become resting latently infected memory B cells
[14,16,22]. Therefore, in the presence of malaria the number of
cells able to tolerate a c-myc translocation (EBV infected) in the
GC are increased and the probability of a c-myc translocation is
also increased (AID activation). Thus, it is the increased
probability of a fortuitous collision of AID and EBV in GC cells,
both exacerbated by malaria that leads to eBL. A further
observation confirming that these events occur within the GC
was the finding that the P. falciparum extract alone had little or no
ability to induce AID. Maximal induction required co-stimulation
Figure 3. P. falciparum extracts stimulate expression of AID protein in normal tonsil B cells. The same protocol was followed as described
in Figure 1, except the cells were analyzed by staining for AID protein expression and FACS analysis after a 5 day incubation period. - Flow cytometry
histograms of cell populations demonstrate equivalent levels of AID expression in B cells activated by CpG or P. falciparum extracts. MFI = Mean
fluorescence intensity. A. and C. Percentage of all B cells expressing AID (B) and percent of B cells expressing high levels of AID (C) suggest equal
levels of AID expression in B cells activated by CpG or P. falciparum extract. We observed two overlapping populations of cells staining positive for
AID. An arbitrary gate imposed on the brighter population defined high level expressers. The same gate was applied to all samples.
doi:10.1371/journal.ppat.1004170.g003
Role of Malaria in Burkitt’s Lymphoma
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Figure 4. Hemozoin is taken up by B cells and activates AID expression. A. Hemozoin (sHz) (red) and CpG (green) were incubated with two
different B cell lines. Note presence of red granules inside both cell types. BL2 is an EBV negative BL line and IM171 a spontaneous EBV positive
lymphoblastoid line. B. Hemozoin stimulates expression of AID mRNA to an equivalent level to that obtained with surface Ig cross-linking and CpG.
The stimulation was independent of hemozoin being complexed with parasite DNA. The same protocol was followed as described in Figure 1. The
cells were analyzed after a 5 day incubation period.
doi:10.1371/journal.ppat.1004170.g004
Role of Malaria in Burkitt’s Lymphoma
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with CD40 ligand and IL-4. This means that the malarial parasite
can only work to induce AID expression if T cell help is also
provided. Since T cell help is specifically provided in the GC
[40,41], this firmly places the role of P. falciparum in the induction
of AID in the GC and would seem to rule out fortuitous activation
elsewhere. This would explain why eBL is uniquely a tumor of GC
cells.
We observed no difference in the percentage of total B cells per
tonsil between the malaria-endemic and the non-malaria regions,
however, GC cells are ,2 fold higher in the malaria background.
This suggests that malaria (or malaria background) does not
disrupt the size of the B cell pool but increases the likelihood that
more B cells, and therefore EBV-infected cells, either enter the GC
or that the cells stay longer in the GC. Either way, this increases
the chances that some B cells, including EBV infected cells, will
develop deleterious mutations and translocations. In individuals
with malaria we detected a wide range in the number of GC cells
containing EBV and in the degree of AID expression. It is
tempting to speculate that those with the rare fortuitous
coincidence of extremely high levels for both may be the likely
candidates for tumor development.
We have provided compelling in vitro evidence to support the
claim that P. falciparum induces AID expression, the first such
evidence. Importantly, the parasite induces AID in an antigen
independent, i.e. deregulated fashion. Such expression is known to
be a predisposing factor for the c-myc translocation. EBV infection
of B cells in vitro, as well as EBV associated proteins, have also been
shown to induce AID expression [42,43,44]. It is conceivable
therefore that EBV and malaria could even cooperate in the
induction of AID.
We have shown that P. falciparum is capable of eliciting AID
expression at least as effectively as the combination of CpG and
BCR cross-linking, suggesting that the parasite can provide both
signals. We have identified hemozoin, the crystalline by product of
P. falciparum digestion of hemoglobin [30] and a reported TLR9
ligand [31,32], as one of the parasite components responsible.
Consistent with its signaling through TLR9, hemozoin is only
effective at inducing AID in the presence of BCR cross-linking.
Thus, it is likely that there is a second, as yet unidentified, parasite
derived ligand that provides the surrogate BCR signal. A likely
candidate for this is the P. falciparum specific protein PfEMP1
encoded by the var gene family [45], which has been shown
previously to bind to and activate B cells through the BCR [46].
This would also explain the specific link of P. falciparum with eBL
since only this species of malaria expresses PfEMP1. The
prediction is therefore, that a combination of hemozoin and
PfEMP1 are providing the requisite TLR9 and sIg signals. Since
TLR9 is a receptor for polynucleotides it was somewhat surprising
that hemozoin was able to stimulate AID expression in the absence
of parasite DNA. It is controversial as to whether hemozoin does
[32] or does not [31] need or be associated with DNA in order to
signal through TLR9. It is possible that hemozoin may be
signaling via a TLR9 independent mechanism in our system since
it has been reported that it can signal through other pathways
including the inflammasome [47,48]. However, there was a high
death rate in our in vitro assays therefore it is possible that
endogenous unmethylated DNA from the dead cells was being
trafficked into the endosomal compartment by hemozoin to
stimulate TLR9 and consequently lead to AID induction.
Demonstration of an increased viral burden of EBV in
individuals with P. falciparum malaria is not a new observation
[25,26], however in this paper we have shown a direct mechanistic
consequence of this elevation that provides a risk factor for eBL
namely an increased number of latently infected cells in the GC.
This effect is not modest, with the mean frequency of EBV
infected GC B cells from the malaria tonsils being about 50 fold
more than the frequency of EBV infected GC B cells from the
controls. Combined with the increase in the number of total GC
Figure 5. Higher levels of AID and c-myc mRNA in tonsil GC B cells from individuals infected with P. falciparummalaria compared to
controls. A. AID mRNA expression is significantly increased in GC B cells from the malaria tonsils. (** p = 0.005). B. c-myc RNA is significantly elevated
in GC B cells from some malaria tonsils. (* p = 0.031). AID and c-myc mRNA levels were normalized to b-actin and the level in the GC population is
expressed relative to that in a standard naı¨ve B cell population (calibrator) isolated from a single Boston tonsil.
doi:10.1371/journal.ppat.1004170.g005
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cells this results on average in there being 70 times more EBV
infected cells in the GCs of individuals with malaria compared to
controls. We have shown previously that healthy individuals have
at any time on average approximately 3 EBV infected cells per GC
[49]. Our results here indicate that this would increase to around
150–200 per GC for an individual with malaria. This is a
significant increase in risk since the consequence is an extremely
high number of (EBV infected) cells each of which are primed to
tolerate the c-myc translocation that emanates from overexpressed
AID.
The increased frequency of latently infected cells seen in the
malaria samples (,50 fold) is very similar to what we have
reported previously for immunosuppressed patients and patients
with SLE [27,50]. Indeed, it has been reported previously that
malaria is immunosuppressive for T cell responses [51], including
those directed against EBV [24]. It is tempting therefore to
speculate that children with malaria are immunosuppressed and
that this explains the risk for eBL. However, we have pointed out
previously that immunosuppression is a risk factor for post-
transplant lymphoproliferative disorder (PTLD)-like disease, i.e.
immunoblastic lymphoma not eBL [14,22]. Thus, immunosup-
pression alone is not sufficient to explain eBL.
The results presented here also provide further support for the
GC model of EBV persistence. This model, which is now generally
accepted, holds that EBV establishes a persistent infection by
driving newly infected blasts through the GC to become latently
infected resting memory B cells [14,16,22]. A direct prediction of
this model is that a higher viral burden should produce a higher
number of EBV infected cells transiting the GC and that
prediction has been fulfilled in this study. Furthermore, the studies
presented here provide a powerful functional confirmation of
the model in that they provide an explanation for the link
between malaria and eBL. Thus, the model predicts that it is the
elevated rate of passage of virus infected cells through the GC,
together with deregulated AID expression, that explains the origin
of eBL.
Our studies suggest that malaria may also induce heightened
expression of c-myc in the GC, at least in some individuals. c-myc
is a non-traditional transcription factor with a very complex
regulation. High c-myc expression in the GC could account for the
observed high rate of proliferation, as well as the high apoptotic
tendency of GC B cells [34,37]. However, the question of whether
c-myc is even expressed in the GC has been controversial in the
past. Martinez-Valdez et al. [37] and Cutrona et al. [34] report
Figure 6. Higher levels of EBV infected cells in tonsil GCs from individuals infected with P. falciparummalaria compared to controls.
A. The percentage of B cells (CD19+) is unchanged. (ns p = 0.18). B. The percentage of GC B cells (CD10+) is significantly elevated in the malaria tonsils
(*** p,0.001). C. The frequency of GC B cells latently infected with EBV is dramatically increased in the malaria tonsils (*** p = 0.001). For details see
Table 1. D. The level of EBV infected GC B cells and AID expression do not directly correlate.
doi:10.1371/journal.ppat.1004170.g006
Role of Malaria in Burkitt’s Lymphoma
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that c-myc is highly expressed in GC B-cells, whereas Klein et al.
[36] were unable to confirm these findings. Recently, Dominguez-
Sola et al. [35] have presented compelling evidence that c-myc is
expressed in GC cells, specifically by B cells selected for reentry
into the dark zone, a conclusion supported by our work.
Furthermore, for AID to target c-myc in GC B cells, c-myc must
be expressed since AID deaminates transcribed substrates and acts
on selected highly transcribed genes when they are over-expressed.
Thus, higher than normal levels of c-myc transcription driven by
malaria could further increase the risk that AID would target the
c-myc gene for a translocation event.
In conclusion, we have presented the first direct evidence for a
mechanism to explain the link between eBL and holoendemic
malaria. If correct, these observations imply that reducing the
exposure to P. falciparum malaria or the development of drugs to
block the ability of malaria to induce AID should dramatically
reduce the incidence of eBL in young children in tropical Africa.
Specifically this should act as a spur to agencies interested in
reducing the incidence of exposure to P. falciparum in young
children.
Methods
Ethical statement
This study was approved by the Institutional Review Board of
the Tufts Medical Center, Boston, USA and the Committee on
Human Research and Ethical Publications of the School of
Medical Sciences, Kwame Nkrumah University of Science and
Technology (KNUST), and Komfo Anokye Teaching Hospital
(KATH), Kumasi Ghana. The material used was deidentified,
discarded tonsil tissue and was deemed exempt from informed
consent by the IRB. The tonsil material was obtained indirectly
either through the Pathology Department at Tufts Medical Center
or the EENT Clinic at Komfo Anokye Teaching Hospital.
Cells, cell lines and tissues
The EBV-positive lymphoblastoid cell line IB4 (gift of Elliott
Kieff) and Namalwa Burkitt’s lymphoma cell line were used as
positive controls for DNA PCR of the W-repeat region of the EBV
genomes. The EBV-negative cell line CB60, a mouse T-cell
hybridoma cell line (gift of Miguel Stadecker) was used as a
Figure 7. c-myc is expressed in GC B cells. A. Flow cytometric analysis demonstrating c-myc expression in tonsil GC cells (CD10+). The arrow
indicate the CD10+, c-myc positive GC population. B. Western blot analysis confirming c-myc expression in 3 independent tonsil GC B cell preparation
(GC1-3). Raji and Rael are EBV positive BL cell lines. The molecular weight in KD is shown to the left. C. ImageStream analysis of c-myc positive tonsil
GC B cells. Staining for a known nuclear protein bcl-6 is shown for comparison. N.B. For this study only Boston control tonsils were used.
doi:10.1371/journal.ppat.1004170.g007
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negative control in all W-PCR experiments. The Burkitt’s
lymphoma cell lines Raji and Rael were used as positive controls
for c-myc western blot. The EBV negative BL2 Burkitt’s
lymphoma cell line and SP-IM 171 spontaneous EBV lympho-
blastic cell line were used in hemozoin-DNA complex internali-
zation assays. All cell lines were cultured at 37uC with 5% CO2 in
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM
glutamine, 2 mM sodium pyruvate, 100 IU of penicillin-strepto-
mycin, and 10 mg/ml ciprofloxacin hydrochloride (RPMI-com-
plete). Palatine tonsils were obtained from patients 14 years or
younger undergoing routine tonsillectomy. Twelve tonsil samples
were obtained from patients at the EENT Clinic Komfo Anokye
Teaching Hospital, Kumasi, Ghana. These were processed at the
Kumasi Center for Collaborative Research in Tropical Medicine
(KCCR), Kumasi, Ghana, stored in liquid nitrogen and shipped to
Tufts University School of Medicine, Boston, USA on dry ice
(under the supervision of Prof. Karen Duca, KNUST, Kumasi,
Ghana). The presence of the parasite was confirmed based on
detection of P. falciparum DNA and/or antigens (see below).
Kumasi is an area of holoendemic malaria therefore it was not
surprising/unexpected that all patient samples received tested
positive for the parasite. To obtain parasite free control samples we
therefore also collected twenty one tonsils from a malaria negative
region (Boston MA) through the Pathology Department at Tufts
Medical Center, Boston MA, USA. The identical procedure and
reagents were used for harvesting tonsils in Boston and Kumasi.
The malaria infected individuals who provided the tonsils are
genetically distinct from the controls and could be subject to a
wider range of infection and lower level of general hygiene. To
minimize this possible source of variation we collected the malaria
tonsils from age and sex matched donors in an area of high
socioeconomic status in Kumasi where economic and medical
standards were comparable to those in Boston.
Isolation of tonsil mononuclear cells
Tonsil tissue was cut into very small pieces in ice-cold PBSA (1x
PBS +0.5% BSA) and then minced. Supernatants were pipetted
through a cell strainer into 50 ml conical tubes to remove debris.
Supernatants were centrifuged at 1,600 rpm at room temperature
for 10 minutes and then aspirated. Pellets were re-suspended and
brought to 50 ml with PBSA. About 25 ml of cells was carefully
layered onto 20 mls of Ficoll-paque plus (GE Healthcare
Biosciences, Philadelphia, USA) and then spun at 2,000 rpm for
30 minutes at room temperature (with no brake). Mononuclear
cells were collected from the interface (buffy coat) and cell pellet
discarded. The volume of mononuclear cells was adjusted to 50 ml
with PBSA (and an aliquot taken for counting); cells were then
washed once by spinning at 1,500 rpm for 10 minutes. After
counting, cells were frozen in fetal bovine serum (FBS) (Sigma, St.
Louis, USA) plus 10% DMSO (dimethyl sulfoxide) at 16108 cells/
ml. Cells were aliquoted in cryotubes and kept on ice for about 5
minutes, stored at 280uC overnight and then transferred to liquid
nitrogen for long term storage. The identical procedure and
reagents were used for preparing tonsil cell suspensions in Boston
and Kumasi.
Extracellular and intracellular staining
Tonsil mononuclear cells were thawed in medium (RPMI/
FBS), and spun down at 1,500 rpm for 5 minutes. B cells were
either first purified using StemSep (StemCell technologies,
Vancouver, Canada) according to manufacturer’s instruction, or
cells were re-suspended in 0.5% BSA in 1x PBS (PBSA) i.e.
staining buffer. Cells were resuspended at 56106 cells/100 ml
PBSA either directly into FACs tubes or 15 ml tubes for staining.
For extracellular staining the appropriate concentration of
fluorochrome conjugated antibody was added to cells in appro-
priate tubes and incubated for 15 minutes at room temperature in
the dark, after thorough mixing. Cells were washed once with
PBSA, vortexed, and spun down at 1,500 rpm for 5 minutes.
Finally cells were re-suspended in 300 ml PBSA and stored at 4uC
until analyzed.
For intracellular staining tonsil cells were pelleted, washed in
Dulbecco’s PBS2 (without calcium or magnesium), and fixed
either with 4% formaldehyde or with BD Cytofix/Cytoperm
fixation and permeabilization solution (BD Biosciences, San Jose,
USA) and then incubated for 20 minutes at room temperature.
Cells were then washed twice either with 1x BD wash/perm buffer
(BD Biosciences, San Jose, USA) or with 0.04% saponin based
wash buffer and spun down at 1,500 rpm for 5 minutes.
Permeabilization buffer (0.5% saponin based buffer) was used to
re-suspend cells at 56106 cells/100 ml. Two microliters (2 ml) of
normal human serum (60 mg/ml, Thermo Fisher Scientific
Rockford, USA) was added in order to block against non-specific
antibody binding, and cells were incubated for 30 minutes at room
temperature. Primary antibodies for intracellular antigens were
added and incubated at room temperature for 30 minutes. Cells
were then washed once and re-suspended in 0.5% saponin based
buffer, 2 ml of normal human serum was again added and
incubated for 30 minutes at room temperature. Fluorochrome
conjugated secondary antibodies were then added at appropriate
dilutions and incubated for 15 minutes in the dark. Cells were
washed once with wash buffer, spun down at 1,500 rpm for 5
minutes and stored in 300 ml PBSA at 4uC until analysis. Cell
sorting was performed on a MoFLo or Influx cell sorter and
analysis on a FACSCalibur or Image Stream at Tufts University
laser cytometry core. Sorted populations were .90% pure.
A list of the antibodies and fluors used in this study is given in
Table S1.
Detection of P. falciparum in tissues
The presence of the parasite was confirmed based on detection
of P. falciparum DNA and/or antigens. Nested, parasite specific
DNA PCR was performed for a sequence in the 2nd exon of the
Chloroquine transporter (Pfcrt) gene as follows: First round (94uC,
3 min; 94uC, 30 sec; 56uC, 30 sec; 60uC, 1 min 30 cycles, 72uC,
3 min) forward primer CCGTTAATAATAAATACACGCAG,
reverse CGGATGTTACAAAACTATAGTTACC (95uC, 5 min;
92uC, 30 sec; 48uC, 30 sec; 65uC, 30 sec (25 cycles); 72uC, 3 min)
forward primer TGTGCTCATGTGTTTAAACTT reverse
ACAAAATTGGTAACTATAGTTTTG. PCR product sizes
were verified on 2% agarose gels. 1st round amplicon 527 bp,
2nd round 145 bp.
P. falciparum antigens were detected employing a rapid
diagnostic test (RDT) cassette (ACON Laboratories, Inc., San
Diego, USA) as directed by the manufacturer.
Limiting dilution analysis to measure the frequency of
EBV infected cells
For limiting dilution analysis, GC B cell (CD19+CD10+)
populations were isolated by flow cytometry and usually 10
replicates each of 26105, 16105, 56104, 2.56104, 1.256104,
0.6256104, 0.31256104 (higher or lower dilutions were added as
needed) were placed in a 96 V bottom plate for subsequent EBV
W-repeat DNA PCR. The plate was spun at 1,200 rpm for 10
minutes at 4uC and the supernatant aspirated. To each well was
then added 20 ml of digestion mix (10X PCR buffer, 100 ml; Igepal
(NP-40) 100 ml; Tween-20 100 ml; Proteinase K 50 ml of 20 mg/
ml stock and 650 ml of water). The plate was sealed air-tight and
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incubated at 55uC overnight. This was followed by proteinase K
deactivation at 95uC for 10 minutes. Ten microliters (10 ml) of water
was then added to all the sample wells. The fraction of EBV positive
wells was then assessed by W-repeat EBV DNA PCR for each
replicate and the frequency of EBV infected cells in the starting
population calculated using Poison statistics. The EBV-positive cell
lines IB4 and Namalwa were used as positive controls and the EBV-
negative cell line CB60 was used as a negative control.
W-repeat EBV DNA PCR
DNA real-time PCR specific for the W-repeat sequence of the
EBV genome was performed as described [52]. For each reaction,
a master mix was prepared, containing 12.5 ml IQ Supermix
(Biorad cat 170-8862), 2.5 ml of 900 nM primers and 2.5 ml of
250 nM fluorogenic probe. Five microliters (5 ml) of DNA was
added to 20 ml of master mix with a final reaction volume of 25 ml.
(See Table S2 for primer and probe sequences). The PCR
reactions were performed on a Biorad iCycler. The protocol was
as follows: Step 1 (1 cycle): 39 at 95uC; Step 2 (50 cycles): 150 at
95uC, 19 at 60uC.
Purification of RNA and RT-PCR
RNA was purified by TRIzol extraction (Invitrogen, Life
Technologies, Grand Island, USA) and then treated with TURBO
DNase (Ambion, Life Technologies, Grand Island, USA) to
eliminate DNA prior to RNA amplification (where necessary).
cDNA was made from the RNA using a cDNA synthesis kit
(Invitrogen iScript cDNA synthesis kit). For the cDNA synthesis
reaction, a master mix was prepared which included 4 ml of 5X
iScript reaction mix, 1 ml of iScript reverse transcriptase, and 8 ml
of nuclease-free water. Seven microliters (7 ml) of purified RNA
was added to 13 ml of master mix. All reactions were performed on
an Applied Biosystems PCR machine (Thermal cycler). The
protocol was as follows: one cycle that included 5 minutes at 25uC,
30 minutes at 42uC, and 5 minutes at 85uC. For real time PCR a
master mix was prepared, containing 12.5 ml of IQ Supermix (Bio-
Rad), 2.5 ml of 900 nM primers, and 2.5 ml of 250 nM fluorogenic
probe, except when Taqman pre-developed assays were being
used in which case, 12.5 ml Supermix, 1.25 ml 20x primer-probe
mix and 6.25 ml water. Five microliters (5 ml) of cDNA was added
to 20 ml of master mix with a final reaction volume of 25 ml. All
real time PCRs were performed on a Bio-Rad iCycler. The
protocol was as follows: step 1, one cycle of 3 minutes at 95uC; step
2, 55 cycles of 15 seconds at 95uC and 1 minute at 60uC. All our
real time PCR assays were optimized to detect down to the single
cell level (See Supplemental Information for a list of primers and
probes).
Preparation of Plasmodium falciparum extract
P. falciparum parasites (3D7 line) were cultured using standard
procedures as described [53]. Parasites were grown at 5%
hematocrit in RPMI 1640 medium, 0.5% AlbuMAX II (Invitro-
gen), 0.25% sodium bicarbonate, and 0.1 mg/ml gentamicin.
Cultures were incubated at 37uC in an atmosphere of 5% oxygen,
5% carbon dioxide, and 90% nitrogen. Parasite extracts were
prepared by selective lysis of the host RBC membranes through
the addition of saponin. Infected RBCs were suspended in 0.01%
saponin in PBS and incubated at room temperature for 5 min.
Host cell free parasites were pelleted by centrifugation, washed
twice with PBS and stored frozen at 280 degrees C. Parasite
extracts were prepared by 3 freeze-thaw cycles of frozen parasites,
sonicated and stored at 280 degrees Celsius until needed. The
protein concentration was determined by the Bicinchoninic assay
(BCA assay – see below).
Stimulation assay
Fresh tonsil mononuclear cells (MNC) were isolated as
described above and re-suspended at ,16106 cells/ml in pre-
warmed PBSA. Two microliters of 5 mM CFSE (carboxyfluor-
escien diacetate, succinimidyl ester) in DMSO (Invitrogen, Life
Technologies, Grand Island, USA) was added per ml of cells (final
concentration 10 mM CFSE). The cells were then incubated for 10
minutes at 37uC. Cells were spun down and re-suspended in 2
volumes of ice-cold culture medium and incubated on ice for 5
minutes. Cells were re-pelleted and re-suspended in 2 volumes ice
cold culture medium (2 times). Washing was done one more time
in 2 volumes of pre-warmed medium and cells were finally re-
suspended in fresh pre-warmed cell culture medium (described
above). A final concentration of 3 mM of CpG-2006 (Hycult
Biotech, Plymouth Meeting, USA), 0.25 mg/ml CD40 ligand
(eBioscience, San Diego, USA), 5 ng/ml IL-4 (eBioscience, San
Diego, USA), 2.5 or 5 mg/ml Anti-human IgG+IgM, (Jackson
ImmunoResearch, West Grove, USA) 10 mg/ml of crude parasite
extract, and hemozoin (InvivoGen, San Diego, USA) 50 mg/ml
were used in the tonsil mononuclear cell stimulation. Cells were
harvested on days 3, 5, 7 and 10, stained with CD19 and then B
cells were sorted with the MoFlo.
Hemozoin internalization assay
Five microgram of human CpG-2006 DNA with a phosphor-
othionate (PTO) backbone bound to Alexa-488 (Integrated DNA
Technologies, Coralville, USA) were mixed with 100 mg/ml of
sonicated synthetic hemozoin [32]and co-incubated with rocking
for 2 h followed by washing of the complex three times with PBS.
Bound and unbound DNA were determined by measuring the
DNA concentration in the collected supernatant, using the
Nanodrop. BL2 and IM 171 cells were each plated at 1 ml (with
approximately 500,000 cells per confocal plate). The CpG-Alexa-
488-hemozoin complex was added to the cell lines BL2 and SP-IM
171, and incubated for 2 hours after which confocal microscopy
was carried out. Confocal reflection microscopy for detection of
hemozoin was combined with fluorescence microscopy to detect
the Alexa-488 tagged CpG on a Leica SP2 AOBS confocal laser-
scanning microscope as described in detail in [54].
Western blot
Cells were spun at 1,500 rpm for 5 minutes and the
supernatant was aspirated. 56106 cells were re-suspended in
100 ml of RIPA buffer (Sigma, St. Louis, USA) with freshly
added protease inhibitors (Thermo Scientific, Rochford, USA).
The sample was pipetted up and down to dislodge cell clumps,
and then vortexed vigorously for 15 seconds then incubated on
ice for ,7 minutes, vortexed again for 15 seconds, spun at
13,200 rpm for 16 minutes at 4uC and the supernatant
transferred to a new eppendorf. Protein concentrations were
determined with either the Bio-Rad protein assay reagent (Bio-
Rad, Hercules, USA) or the bicinchoninic acid (BCA) protein
assay reagent mix (Thermo Scientific, Rockford, USA), accord-
ing to manufacturer’s instruction. To each protein sample was
added 12.5% beta mercaptoethanol and 16 SDS sample buffer
(Boston Bioproducts, Ashland, USA). Five microliters of protein
standard (Biorad, Hercules, USA) was added to designated
well(s). Samples were heated at 95uC for 5 minutes and resolved
on 4–20% Tris-Glycine gels (Invitrogen, Life Technologies,
Grand Island, USA). Immobilon-P polyvinylidene fluoride
(PVDF) transfer membrane (Millipore, Billerica, USA) was used
in a semi-dry electrophoretic transfer. The membrane was
blocked with either membrane blocking solution (Invitrogen, Life
Technologies, Grand Island, USA) or 5% milk in 1x Tris
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buffered saline with Tween 20 (TBST) (Cell signaling, Danvers,
USA) at room temperature for 1 hr. The PVDF membrane was
then incubated with primary antibody in appropriate blocking
buffer at 4uC overnight. The membrane was washed in TBST or
Invitrogen wash solution three times, 10 minutes each and
incubated with secondary antibody in 5% milk in TBST for 45
minutes at room temperature. The membrane was then washed
with Invitrogen wash solution 4 times, 10 minutes each at room
temperature and then enhanced chemiluminescence (ECL)
reagent SuperSignal west femto maximum sensitivity substrate
(Thermo Fisher scientific, Rockford, USA) was applied to the
membrane. Hyblot CL autoradiography film (Denville scientific,
Metuchen, USA) was then exposed to the membrane and
developed in a Kodak X-MAT 2000 processor.
Statistical analysis
Data are expressed as mean 6 SD. Differences between groups
were analyzed for statistical significance with Student two-tailed,
unpaired t test. Significance was considered achieved when the p
value was ,0.05.
Supporting Information
Table S1 The antibodies used in this study.
(DOCX)
Table S2 The primers and probes used in this study.
(DOCX)
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